Search for Studies
Search Results
A multi-center, randomized trial to examine the effect of aggressive risk factor control and arrhythmia trigger-based intervention on recurrence of atrial fibrillation.
Conditions:
Atrial FibrillationLocation:
- St. Paul's Hospital, Vancouver, British Columbia, Canada
- St. Mary's General Hospital, Kitchener, Ontario, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Sacre Coeur Hospital, Montreal, Quebec, Canada
- Kelowna General Health, Kelowna, British Columbia, Canada
- Hamilton Health Sciences Center, Hamilton, Ontario, Canada
- St. Michael's Hospital, Toronto, Ontario, Canada
- Montreal Heart Institute, Montreal, Quebec, Canada
- Foothills Hospital, Calgary, Alberta, Canada
- Saint John Regional Hospital, Saint John, New Brunswick, Canada
- Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada
- London Health Sciences Center, London, Ontario, Canada
- QE II Health Sciences Centre, Halifax, Nova Scotia, Canada
- Ottawa Heart Institute, Ottawa, Ontario, Canada
- Laval Hospital, Laval, Quebec, Canada
- Regina General Hospital, Regina, Saskatchewan, Canada
- McGill University Health Centre, Montreal, Quebec, Canada
Sex:
ALLAges:
Over 18The goal of this multi-centre phase I/II open-label, single-arm study is to determine the safety, feasibility, therapeutic dose, and preliminary efficacy of psilocybin microdosing to treat psychological distress among patients with advanced illness. Forty patients will receive psilocybin drug product (1-3mg per day, Mon-Fri) for 4 weeks to be administered via oral capsules by the participant. Feasibility (recruitment rate, rate of intervention and follow-up completion), safety (rate of adverse events), dosing, and preliminary efficacy (depression, anxiety, overall well-being, and global impression of change) will be measured.
Conditions:
Depression, Anxiety | Distress, EmotionalLocation:
- Bruyere Continuing Care, Ottawa, Ontario, Canada
- The Ottawa Hospital, Ottawa, Ontario, Canada
Sex:
ALLAges:
Over 18This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.
Conditions:
Non-small Cell Lung CancerLocation:
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Sex:
ALLAges:
Over 18Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Conditions:
Locally Advanced (Inoperable) or Metastatic Breast CancerLocation:
- Research Site, Kelowna, British Columbia, Canada
- Research Site, Brampton, Ontario, Canada
- Research Site, Sherbrooke, Quebec, Canada
- Research Site, Abbotsford, British Columbia, Canada
- Research Site, Halifax, Nova Scotia, Canada
- Research Site, Toronto, Ontario, Canada
- Research Site, Moncton, New Brunswick, Canada
- Research Site, Sault Ste. Marie, Ontario, Canada
- Research Site, Winnipeg, Manitoba, Canada
- Research Site, Ottawa, Ontario, Canada
Sex:
ALLAges:
18 - 99Primary Objectives: * To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable. * To evaluate the time-course of AD and selected atopic comorbidities. Secondary Objectives: * To characterize disease burden and unmet need. * To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching). * To document the real-world effectiveness and safety of treatments.
Conditions:
Dermatitis AtopicLocation:
- Investigational Site Number : 1240004, Calgary, Alberta, Canada
- Investigational Site Number : 1240001, Markham, Ontario, Canada
- Investigational Site Number : 1240010, Halifax, Nova Scotia, Canada
- Investigational Site Number : 1240009, Regina, Saskatchewan, Canada
- Investigational Site Number : 1240005, Winnipeg, Manitoba, Canada
- Investigational Site Number : 1240006, Montreal, Quebec, Canada
- Investigational Site Number : 1240007, Calgary, Alberta, Canada
- Investigational Site Number : 1240008, Toronto, Ontario, Canada
Sex:
ALLAges:
Under 11The growth and development of lean body mass (i.e., muscle and bone) is instrumental to health and performance across the lifespan, especially in youth, as they actively experience growth. Thus, it is important to capitalize on physical activity and nutrition (especially dietary protein), to support the accretion of lean tissues. Eating a protein-rich meal or performing physical activity can stimulate protein synthesis, and when repeated over time, lean body mass accretion. There is currently an increasing market demand for non-dairy alternatives, due to multiple reasons including environmental, ethical, or taste preferences. However, it is important to understand how different beverages may support 'growth' (anabolism) of lean tissues after exercise. Research in adults has shown that dairy milk is superior to non-dairy milk beverages for supporting post-exercise recovery and muscle protein synthesis. However, the impact of dairy and non-dairy milk alternatives on recovery from exercise is not well understood in children. By understanding the milk beverage that best supports post-exercise recovery, the investigators can determine the optimal nutritional environment to facilitate the growth of lean tissues in the body.
Conditions:
Dietary Proteins | Indicator Amino Acid OxidationLocation:
- Goldring Centre for High Performance and Sport, Toronto, Ontario, Canada
Sex:
ALLAges:
8 - 16The primary objective of this study will be to determine the influence of a presleep vitamin C-enriched, collagen-modelled supplement (CVC) on the metabolic fate of dietary glycine using a \[2H5\]glycine tracer within the intramuscular connective tissue at rest and after a bout of resistance exercise. Other outcomes will be related to regulation collagen remodelling in skeletal muscle.
Conditions:
InterventionalLocation:
- Goldring Centre for High Performance Sport at the University of Toronto, Toronto, Ontario, Canada
Sex:
ALLAges:
18 - 35The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.
Conditions:
MesotheliomaLocation:
- Novartis Investigative Site, Montreal, Quebec, Canada
Sex:
ALLAges:
18 - 120This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by Alzheimer's Disease and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of Alzheimer's Disease and associated cognitive changes.
Conditions:
Alzheimer's DiseaseLocation:
- The Douglas Research Centre, Montréal, Quebec, Canada
Sex:
ALLAges:
Over 18The Hydrocephalus Clinical Research Network (HCRN) has been established by philanthropic funding to conduct multi-institutional research (clinical trials and observational studies) on pediatric hydrocephalus. In addition to philanthropic funding, the HCRN has also received an NIH NINDS Challenge Grant to support the network infrastructure which allows for the conduct of this and other network studies. The HCRN consists of multiple Clinical Centers and the Data Coordinating Center (DCC). The HCRN Core Data Project will obtain data about all neurosurgical hydrocephalus events from the network Clinical Centers, and create a database to be used by HCRN investigators. The ongoing maintenance of the Core Data Project serves two main purposes: 1) it will help investigators understand the variability, progression, and current treatment practices for hydrocephalus in children, with an ultimate goal of better guiding and assessing therapeutic intervention and providing recommendations on patient care and, 2) it will provide pilot and descriptive data necessary for hypothesis generation and study design (i.e. preliminary power analyses, recruitment projections) for studies under development by the HCRN. This multi-institutional database will be maintained throughout the lifetime of the HCRN, and may be useful for tracking trends in pediatric hydrocephalus over time. The Core Data Project will be an invaluable resource to the HCRN and will help stimulate new research protocols, identify potential need for future expansion of the network to incorporate additional patient populations, and provide a descriptive understanding of children with hydrocephalus cared for within the network.
Conditions:
Pediatric HydrocephalusLocation:
- Alberta Children's Hospital, Calgary, Alberta, Canada
- Sick Children's Hospital, Toronto, Ontario, Canada
- British Columbia Children's Hospital, Vancouver, British Columbia, Canada